Holen Sie sich die Stockscreener-App
0.84
0.11%
-0.0009
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
The Manufacturers Life Insurance Company Boosts Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
US Penny Stocks: 3 Picks With Market Caps Under $200M - Simply Wall St
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - The Manila Times
XOMA Royalty Acquires Pulmokine for $20 Million Adding the - GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio - Benzinga
Gossamer Bio: Q3 Earnings Snapshot - Marketscreener.com
Adicet Bio Inc (NASDAQ: ACET) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
GSA Capital Partners LLP Invests $67,000 in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Inc (GOSS)Monday, Aug 26, 2024 - Smartkarma
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy - MSN
US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
Leerink Partnrs Raises Earnings Estimates for Gossamer Bio - Defense World
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS) - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Gossamer Bio - MarketBeat
FMR LLC's Strategic Acquisition of Gossamer Bio Inc Shares - GuruFocus.com
Industry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue Forecasts - Yahoo Finance
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Gossamer Bio Grants 183K Stock Options to New Hires at $0.88 Per Share | GOSS Stock News - StockTitan
Gossamer Bio (NASDAQ:GOSS) Earns Buy Rating from HC Wainwright - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations - TipRanks
GOSSGossamer Bio, Inc. Latest Stock News & Market Updates - StockTitan
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now - The Manila Times
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short Interest - Defense World
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity - Yahoo Finance
3 US Penny Stocks With Market Caps Under $900M To Consider - Simply Wall St
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
It makes sense and dollars to buy Gossamer Bio Inc (GOSS) stock - SETE News
Financial Fitness Check: Examining Gossamer Bio Inc (GOSS)’s Key Ratios - The Dwinnex
Gossamer Bio Inc (GOSS) rating initates by Oppenheimer - Knox Daily
Millennium Management LLC Sells 898,042 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Millennium Management LLC - MarketBeat
The Attractiveness of Investing In Gossamer Bio Inc (GOSS) is Growing - Knox Daily
Investor’s Delight: Gossamer Bio Inc (GOSS) Closes Weak at 1.02, Down -2.86 - The Dwinnex
GOSS underperforms with a -2.86 decrease in share price - US Post News
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Gossamer Bio Inc [NASDAQ: GOSS] Sees Decrease in Stock Value - Knox Daily
Marshall Wace LLP Boosts Position in Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat
Several Insiders Invested In Gossamer Bio Flagging Positive News - Yahoo Finance
Analyzing Northwest Biotherapeutics (OTCMKTS:NWBO) and Gossamer Bio (NASDAQ:GOSS) - Defense World
Navigating GOSS’s Stock Market Maze: Ups and Downs in 2023 - The InvestChronicle
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - Yahoo Finance
A better buy-in window may exist right now for Gossamer Bio Inc (GOSS) - SETE News
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 5.8% in September - Defense World
Analysts review Gossamer Bio Inc’s rating - Knox Daily
GOSS (Gossamer Bio Inc) has impressive results - US Post News
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):